CAR-M therapy is a promising tumor treatment strategy with distinctive phagocyitc capabilities, antigen-presenting prorerties, and the ability to activate adaptive immunity (Fig. 6).In this study, we constructed CD26 CAR-M using mouse-derived macrophages Raw264.7 and overexpressed CD26 in murine CML cell lines, BP210 and BP210-T315I. This evidence concerns the gene DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive.